UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

BMC cancer, 2018-05, Vol.18 (1), p.598-598, Article 598

2018

Link zum Volltext

Verfügbarkeit prüfen

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A390-A390

2021

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1986-1991

2023

Link zum Volltext

Verfügbarkeit prüfen

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

International journal of cancer, 2021-05, Vol.148 (10), p.2557-2570

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Clinical cancer research, 2022-08, Vol.28 (16), p.3489-3498

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.243-243

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study

Journal of clinical oncology, 2018-06, Vol.36 (18_suppl), p.LBA4-LBA4

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

Journal of clinical oncology, 2019-06, Vol.37 (18_suppl), p.LBA4007-LBA4007

2019

Link zum Volltext

Verfügbarkeit prüfen

EN2-2. Pembrolizumab vs chemotherapy in untreated PD-L1-positive metastatic NSCLC : KEYNOTE-042 5y update

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.550-550

2021

Link zum Volltext

Verfügbarkeit prüfen

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

Anti-cancer drugs, 2013-11, Vol.24 (10), p.1084-1092

2013

Link zum Volltext

Verfügbarkeit prüfen

Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

Latvijas k̦̦irurg̓ijas žurnāls, 2013-12, Vol.13 (1), p.63-70

2013

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and Predictive Significance of Breast Cancer Stem Cells

Latvijas k̦̦irurg̓ijas žurnāls, 2011-01, Vol.11 (1), p.122-125

2011

Link zum Volltext

Verfügbarkeit prüfen

The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin

Molecular imaging and biology, 2005-05, Vol.7 (3), p.236-243

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study

EN2-2. Pembrolizumab vs chemotherapy in untreated PD-L1-positive metastatic NSCLC : KEYNOTE-042 5y update

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

Prognostic and Predictive Significance of Breast Cancer Stem Cells

The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin

Suchergebnisse filtern